Literature DB >> 27895169

Critical Role of LTB4/BLT1 in IL-23-Induced Synovial Inflammation and Osteoclastogenesis via NF-κB.

Laura Bouchareychas1, Eva M Grössinger1, Mincheol Kang1, Hong Qiu1, Iannis E Adamopoulos2,3.   

Abstract

IL-23 activates the synthesis and production of leukotriene B4 (LTB4) in myeloid cells, which modulate inflammatory arthritis. In this study we investigated the role of LTB4 and its receptor LTB4R1 (BLT1) in synovial inflammation and osteoclast differentiation. Specifically, we used IL-23 in vivo gene transfer to induce arthritis in mice and showed that elevated serum LTB4 and synovial expression of 5-lipoxygenase correlated with increased disease severity by histological evaluation and paw swelling compared with GFP gene transfer controls. To further investigate the effect of the LTB4 pathway in bone loss, we performed osteoclast differentiation assays by stimulating with M-CSF and receptor activator of NF-κB ligand bone marrow cells derived from BLT1+/+ and/or BLT1-/- mice and used quantitative PCR for gene expression analysis in terminally differentiated osteoclasts. Deficiency in BLT1 resulted in the upregulation of osteoclast-related genes and an increase in the formation of giant, multinucleated TRAP+ cells capable of F-actin ring formation. Additionally, BLT1 deficiency showed an increase of phosphorylated NF-κB and phosphorylated IκB levels in osteoclasts. We also performed real-time calcium imaging to study the effect of BLT1 deficiency in receptor activator of NF-κ-B ligand-induced activation of intracellular calcium flux in vitro. Our data show that LTB4 and its receptor BLT1 exacerbate synovial inflammation in vivo and bone resorption in vitro, suggesting that LTB4 and BLT1 could be effectively targeted for the treatment of musculoskeletal diseases.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27895169      PMCID: PMC5173389          DOI: 10.4049/jimmunol.1601346

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo.

Authors:  Zhi-Ying Chen; Cheng-Yi He; Mark A Kay
Journal:  Hum Gene Ther       Date:  2005-01       Impact factor: 5.695

2.  IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass.

Authors:  Iannis E Adamopoulos; Marlowe Tessmer; Cheng-Chi Chao; Sarvesh Adda; Dan Gorman; Mary Petro; Chuan-Chu Chou; Robert H Pierce; Wei Yao; Nancy E Lane; Drake Laface; Edward P Bowman
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

3.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

4.  Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression.

Authors:  Carlos H Serezani; Casey Lewis; Sonia Jancar; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

5.  Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo.

Authors:  C Garcia; B F Boyce; J Gilles; M Dallas; M Qiao; G R Mundy; L F Bonewald
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

6.  The clinical role of IL-23p19 in patients with rheumatoid arthritis.

Authors:  H-R Kim; H-S Kim; M-K Park; M-L Cho; S-H Lee; H-Y Kim
Journal:  Scand J Rheumatol       Date:  2007 Jul-Aug       Impact factor: 3.641

7.  Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms.

Authors:  Krishnaprasad Subbarao; Venkatakrishna R Jala; Steven Mathis; Jill Suttles; Wolfgang Zacharias; Jasimuddin Ahamed; Hydar Ali; Michael T Tseng; Bodduluri Haribabu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-12-01       Impact factor: 8.311

8.  A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis.

Authors:  Nancy D Kim; Richard C Chou; Edward Seung; Andrew M Tager; Andrew D Luster
Journal:  J Exp Med       Date:  2006-03-27       Impact factor: 14.307

9.  A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury.

Authors:  Daniela Dal-Secco; Jing Wang; Zhutian Zeng; Elzbieta Kolaczkowska; Connie H Y Wong; Björn Petri; Richard M Ransohoff; Israel F Charo; Craig N Jenne; Paul Kubes
Journal:  J Exp Med       Date:  2015-03-23       Impact factor: 14.307

10.  Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils.

Authors:  W W Huang; E A Garcia-Zepeda; A Sauty; H C Oettgen; M E Rothenberg; A D Luster
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  19 in total

1.  [Pathogenic role of leukotriene B4 in pulmonary microvascular endothelial cell hyper- permeability induced by one lung ventilation in rabbits].

Authors:  Li-Sha Li; Yong Yang; Xin-Ling Liu; Chuan-Rao Zhang; Qing-Yan Ye; Wen-Jun Hou; Yan-Hua Zhao; Gao-Peng Xiao; Xin-Nan Li; Yan-Hua Li; Rui Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

Review 2.  Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.

Authors:  Cuong Thach Nguyen; Yehudi Bloch; Katarzyna Składanowska; Savvas N Savvides; Iannis E Adamopoulos
Journal:  Clin Immunol       Date:  2018-09-06       Impact factor: 3.969

3.  Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis.

Authors:  Yanpeng Ma; Longlong Liu; Bin Li; Wenyao Wang; Tingting Zhao
Journal:  Immun Inflamm Dis       Date:  2022-06

4.  Paeoniflorin ameliorates collagen-induced arthritis via suppressing nuclear factor-κB signalling pathway in osteoclast differentiation.

Authors:  Haiyan Xu; Li Cai; Lili Zhang; Guojue Wang; Rongli Xie; Yongshuai Jiang; Yuanyang Yuan; Hong Nie
Journal:  Immunology       Date:  2018-02-17       Impact factor: 7.397

5.  Macrophage Exosomes Resolve Atherosclerosis by Regulating Hematopoiesis and Inflammation via MicroRNA Cargo.

Authors:  Laura Bouchareychas; Phat Duong; Sergio Covarrubias; Eric Alsop; Tuan Anh Phu; Allen Chung; Michael Gomes; David Wong; Bessie Meechoovet; Allyson Capili; Ryo Yamamoto; Hiromitsu Nakauchi; Michael T McManus; Susan Carpenter; Kendall Van Keuren-Jensen; Robert L Raffai
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

6.  Constitutive activation of the NEAT1/miR-22-3p/Ltb4r1 signaling pathway in mice with myocardial injury following acute myocardial infarction.

Authors:  Lijie Wang; Lu Wang; Qi Wang
Journal:  Aging (Albany NY)       Date:  2021-06-03       Impact factor: 5.682

Review 7.  Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis.

Authors:  Jie Huang; Xuekun Fu; Xinxin Chen; Zheng Li; Yuhong Huang; Chao Liang
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

Review 8.  The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.

Authors:  Wida Razawy; Marjolein van Driel; Erik Lubberts
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

9.  γδTCR regulates production of interleukin-27 by neutrophils and attenuates inflammatory arthritis.

Authors:  Laura Bouchareychas; Eva M Grössinger; Mincheol Kang; Iannis E Adamopoulos
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

10.  Ca2+-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis.

Authors:  Eva M Grössinger; Mincheol Kang; Laura Bouchareychas; Ritu Sarin; Dominik R Haudenschild; Laura N Borodinsky; Iannis E Adamopoulos
Journal:  J Immunol       Date:  2017-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.